Let us help you
Named Patient Program
Name Patient Program, often referred to as NPP, are initiatives established to provide controlled and regulated access to investigational or unapproved medical treatments for patients who have exhausted other treatment options and meet specific eligibility criteria.
The primary purpose of Name patient program is to offer access to potentially life-saving or disease-altering therapies when the prescribed Medicines not approved in the patient’s country but are approved and available in at other countries.
These programs go by various names, including Compassionate Use, Manage Access Program, and Individual Patient Request, among others. The terminology may vary depending on the region and its regulatory framework.
Alleviare Life Sciences assists eligible patients to access specific medicines. To initiate a request, the treating physician or the patient in need of a particular medicinal product must submit the request to Alleviare.
For Indian Patient inquires under NPP.
To submit a request, please access the portal through the provided link. For further inquiries or to contact Alleviare, you can reach out via email to our dedicated team at:
Call / WhatsApp Number
+91 9289711088 (Ms. Laxmi Singh)
For any urgent inquiries or assistance needed, please reach out to our Support Team. Rest assured, we will respond within 24 hours, from Monday to Saturday, during the hours of 9:00 A.M to 18:00 PM.
Export / IMPORT all Specialty Drugs
Our specialty pharmacy service provides support for the following medications. *This list is not all-inclusive. Please contact our team for details concerning other available products.
Oncology | Inflammatory Conditions | Hepatitis | Multiple Sclerosis and Neurology | Human Immunodeficiency Virus (HIV) | Pulmonary Arterial Hypertension | Hematology | Hemophilia | Infertility | Transplant | Growth Hormone Deficiency | and more
Named Patient Basis Access
Named Patient Programs provide controlled access to drugs in response to requests by physicians on behalf of specific, or “named,” patients when those medicines are not licensed in the patient’s country.